Vaccination — Cost, Top Hospitals & Success Rates | MyMedicPlus

Vaccination is the administration of a biological preparation — a vaccine — to stimulate the body's immune system to develop adaptive immunity against a specific infectious disease or pathogen. The word 'vaccine' derives from the Latin vacca (cow), after Edward Jenner's 1796 observation that milkmaids exposed to cowpox (vaccinia) were protected against the far more deadly smallpox — the first scientific demonstration of immunization.

Modern vaccines work by presenting the immune system with an antigen — a molecule recognised as foreign — in a form that triggers an immune response without causing disease. This response involves the production of specific antibodies by B lymphocytes and the formation of memory T and B cells. Upon subsequent exposure to the actual pathogen, these memory cells enable a rapid, amplified immune response that neutralizes the infection before it can establish itself and cause illness.

Vaccination is the single most effective preventive health intervention after clean water supply. The WHO estimates that vaccines prevent 3.5 to 5 million deaths per year globally. Diseases that once killed or disabled millions annually — smallpox, poliomyelitis, diphtheria, measles — have been eradicated or brought to historically low levels through vaccination programs. Smallpox, the deadliest infectious disease in human history (killing an estimated 300 million people in the 20th century alone), was declared globally eradicated in 1980 following a coordinated WHO vaccination campaign.

Vaccination is relevant throughout life — not only in childhood. Adults require booster doses to maintain immunity, new vaccines are recommended at various life stages (e.g., herpes zoster vaccine from age 50), and specific populations including pregnant women, immunocompromised individuals, and international travelers have tailored vaccination requirements.

Vaccines target a broad spectrum of bacterial, viral, and toxin-mediated diseases. The following are the principal vaccine-preventable diseases (VPDs) by age group:

Infants and Children

• Measles, Mumps, Rubella (MMR): Measles causes pneumonia, encephalitis, and death; mumps causes orchitis and deafness; rubella in pregnancy causes congenital rubella syndrome. The combined MMR vaccine provides >97% protection.
• Diphtheria, Tetanus, Pertussis (DTaP/DTP): Diphtheria causes airway obstruction and myocarditis; tetanus causes fatal muscle spasms; pertussis (whooping cough) causes prolonged respiratory illness and infant death.
• Haemophilus influenzae type b (Hib): Leading cause of bacterial meningitis and epiglottitis in children under 5 years before vaccine introduction.
• Pneumococcal disease: Streptococcus pneumoniae causes pneumonia, meningitis, and septicaemia; pneumococcal conjugate vaccines (PCV13, PCV15, PCV20) significantly reduce invasive pneumococcal disease.
• Rotavirus gastroenteritis: The leading cause of severe dehydrating diarrhoea in children under 5; rotavirus vaccines reduce hospitalisation for gastroenteritis by 50–80%.
• Poliomyelitis: Inactivated polio vaccine (IPV) and oral polio vaccine (OPV) have brought poliovirus to the verge of global eradication.
• Varicella (Chickenpox): Can cause bacterial superinfection, pneumonia, and encephalitis; varicella vaccine reduces hospitalisation by 90%.

Adolescents and Adults

• Human papillomavirus (HPV): HPV types 16 and 18 cause approximately 70% of cervical cancers and also cause cancers of the oropharynx, vulva, vagina, anus, and penis. HPV vaccines (Gardasil 9) prevent 9 high-risk HPV types.
• Meningococcal disease: Neisseria meningitidis serogroups A, B, C, W, Y cause rapidly fatal meningitis and septicaemia; vaccines for all major serogroups are available.
• Influenza: Annual influenza vaccination is recommended for all adults; it prevents 40–60% of infections in years of good vaccine-strain match and significantly reduces severe disease and hospitalisation.
• Hepatitis A and B: Hepatitis B vaccination prevents chronic hepatitis B, cirrhosis, and hepatocellular carcinoma — one of the most common cancers worldwide.

Older Adults

• Herpes zoster (Shingles): Reactivation of varicella-zoster virus causing dermatomal pain rash and potentially debilitating post-herpetic neuralgia; recombinant zoster vaccine (Shingrix) is >90% effective in adults ≥50 years.
• Pneumococcal pneumonia: Particularly severe in adults ≥65 and those with chronic diseases; pneumococcal vaccines recommended for all older adults.
• COVID-19: mRNA and other COVID-19 vaccines substantially reduce the risk of severe disease, hospitalisation, and death, particularly in high-risk populations.

Vaccination is recommended for essentially all individuals across the lifespan, with the specific vaccines and timing determined by national immunization schedules adapted to local disease epidemiology, age-specific immunological considerations, and risk factors.

Infants and Children

The primary immunization series — the foundation of a lifetime of vaccine protection — begins at birth (hepatitis B, BCG in many countries) and continues through the first 18 months of life. Completion of the childhood schedule is critical, as young children are most vulnerable to the severest complications of vaccine-preventable diseases. School entry vaccination requirements in many jurisdictions mandate up-to-date immunization as a public health measure.

Pregnant Women

Certain vaccines are specifically recommended during pregnancy: the inactivated influenza vaccine (reduces maternal and neonatal influenza risk) and the Tdap vaccine (27–36 weeks gestation) to provide newborns with transplacental pertussis antibodies before they are old enough to complete their own primary series. Live attenuated vaccines (MMR, varicella, BCG, live typhoid) are contraindicated in pregnancy due to theoretical fetal risk.

Immunocompromised Individuals

People living with HIV, those on immunosuppressive therapy (chemotherapy, high-dose corticosteroids, anti-TNF biologics, post-transplant immunosuppression) require careful individualized vaccination planning. Inactivated vaccines are generally safe; live vaccines are usually contraindicated. Response may be suboptimal and additional doses or serological confirmation of immunity may be needed. Vaccinating household contacts of immunocompromised individuals is also important to reduce transmission risk.

Travellers

International travel to certain regions requires or strongly recommends additional vaccines: yellow fever vaccination certificate mandatory for entry to some sub-Saharan African and South American countries; typhoid, hepatitis A, hepatitis B, meningococcal, and rabies vaccines recommended for varying destinations. Travel health clinics assess destination, itinerary, activities, and health history to provide personalised pre-travel vaccination advice.

Healthcare Workers

Healthcare professionals face occupational exposure to vaccine-preventable diseases. Annual influenza, hepatitis B with confirmed seropositivity, Tdap, measles/mumps/rubella immunity, varicella immunity, and in some regions meningococcal and COVID-19 vaccines are mandatory or strongly recommended by occupational health programmes.

Vaccine technology has evolved dramatically from early live and inactivated whole-pathogen preparations to highly sophisticated molecular platforms:

By Technology Platform

• Live attenuated vaccines: Derived from pathogens weakened by serial passage in culture (MMR, varicella, BCG, yellow fever, oral rotavirus). These replicate briefly in the recipient, generating a broad and durable immune response often comparable to natural infection, typically with 1–2 doses.
• Inactivated vaccines: Killed whole organisms (hepatitis A, inactivated influenza, inactivated polio). Require multiple primary doses and periodic boosters as they do not replicate in the host.
• Subunit vaccines: Purified protein antigens (acellular pertussis components of DTaP, hepatitis B surface antigen). Highly specific, safe across all immune states, often adjuvanted to enhance immunogenicity.
• Conjugate vaccines: Polysaccharide antigens from bacterial capsules linked to carrier proteins to stimulate T-cell-dependent immunity in infants (Hib, meningococcal, pneumococcal conjugate vaccines).
• Toxoid vaccines: Chemically inactivated bacterial toxins (tetanus toxoid, diphtheria toxoid — components of DTP and Tdap).
• mRNA vaccines: Lipid nanoparticle-encapsulated messenger RNA encoding a target antigen (e.g., SARS-CoV-2 spike protein). The cell translates the mRNA into protein, triggering immune response. No DNA alteration occurs. Platform allows extremely rapid development.
• Viral vector vaccines: Recombinant adenovirus or other viral vector carrying antigen-encoding genes (Oxford-AstraZeneca COVID-19, Janssen COVID-19, Ebola vaccines). Effective cellular and humoral immunity.
• Virus-like particle (VLP) vaccines: Self-assembling protein shells resembling viral capsids but containing no genetic material (HPV vaccines Gardasil/Cervarix).

Routes of Administration

The vast majority of vaccines are administered by intramuscular injection (deltoid muscle in adults; anterolateral thigh in infants). Some are given subcutaneously (MMR, varicella). Oral vaccines include rotavirus, oral polio, oral typhoid, and oral cholera. The live attenuated influenza vaccine (LAIV) is administered as a nasal spray. Needle-free delivery platforms (microneedle patches, jet injectors) are in advanced development and may expand vaccine access in resource-limited settings.

The benefits of vaccination are documented by over two centuries of epidemiological evidence and are among the most compelling in all of medicine:

Individual Health Benefits

• Prevention of illness: Vaccines provide direct, specific protection against the targeted pathogen — with efficacy rates ranging from approximately 60% (annual influenza) to >99% (measles, hepatitis A) in fully vaccinated individuals.
• Prevention of complications: Vaccination prevents not just the primary infection but also its potentially devastating complications — measles encephalitis, pertussis-associated infant death, HPV-associated cancers, hepatitis B-induced cirrhosis and liver cancer, and post-herpetic neuralgia.
• Reduced antibiotic dependence: By preventing bacterial infections (pneumococcal disease, Hib, pertussis) and viral infections that lead to secondary bacterial complications, vaccines reduce antibiotic prescribing and thus help combat antimicrobial resistance.
• Cancer prevention: HPV vaccination prevents cervical, oropharyngeal, vulval, vaginal, penile, and anal cancers. Hepatitis B vaccination prevents hepatocellular carcinoma. These represent the clearest examples of vaccine-preventable cancer.

Community and Societal Benefits

• Herd protection: High community vaccination rates (typically ≥95% for measles; ≥80–85% for influenza) create population-level barriers to disease transmission, protecting unvaccinated vulnerable individuals.
• Elimination and eradication: Sustained high coverage eliminates endemic disease transmission from geographic regions and, ultimately, eradicates disease globally (as achieved with smallpox).
• Economic productivity: Vaccination reduces absenteeism from school and work, prevents long-term disability, and dramatically reduces hospitalisation costs. Modelling studies consistently show vaccination programs to be highly cost-effective or cost-saving even when vaccine procurement costs are included.

Vaccines are among the most carefully evaluated medical products, subject to extensive pre-licensure clinical trials and continuous post-licensure safety surveillance. Side effects are generally mild and transient:

Very Common (Occur in >1 in 10 Recipients)

• Injection site reactions: Pain, redness (erythema), and swelling at the injection site. These resolve spontaneously within 1–3 days and are a normal immune response to the vaccine antigen and adjuvant.
• Systemic reactions: Fatigue, mild headache, and low-grade fever (particularly after mRNA COVID-19 vaccines and live vaccines). These typically resolve within 24–48 hours and indicate the immune system is responding appropriately.
• Irritability in infants: Common after DTP vaccination; usually self-limiting within 24 hours.

Uncommon (Occur in 1 in 100 to 1 in 1,000 Recipients)

• Moderate fever (>39°C) following MMR or MMRV in young children.
• Febrile seizures — rare, brief, and without long-term neurological consequences — associated with MMR-related fever in 1 in 3,000 recipients aged 12–23 months.
• Local abscess at BCG injection site if administered incorrectly (subcutaneous rather than intradermal).

Rare Serious Adverse Events (<1 in 100,000 Recipients)

• Anaphylaxis: Severe, potentially life-threatening allergic reaction occurring within 15 minutes of administration. Incidence approximately 1.31 per million vaccine doses. Managed with prompt administration of intramuscular epinephrine; all vaccination sites maintain emergency protocols and observe recipients for a minimum of 15 minutes post-vaccination.
• Vaccine-associated paralytic polio (VAPP): An extremely rare complication of oral polio vaccine (OPV); approximately 1 case per 2.7 million doses. Eliminated in countries that have switched exclusively to inactivated polio vaccine (IPV).
• Intussusception: A rare bowel obstruction previously associated with first-generation oral rotavirus vaccine (RotaShield, withdrawn 1999). Current WHO-prequalified rotavirus vaccines (Rotarix, RotaTeq) have not shown a clinically significant association in post-licensure surveillance.

Scientific Consensus on Vaccine Safety

Extensive research has definitively established that there is no causal link between MMR vaccination and autism — a claim originating from a 1998 study that was retracted by the Lancet and whose lead author lost his medical licence due to ethical violations and data fraud. More than 20 large-scale epidemiological studies involving millions of children confirm vaccines do not cause autism.

Understanding what happens after vaccination helps individuals and parents manage expected reactions appropriately and ensures adherence to the complete immunization schedule.

Immediate Post-Vaccination Period (0–30 Minutes)

All recipients should remain at the vaccination site for a minimum of 15 minutes (30 minutes for individuals with a history of severe allergic reactions) after receiving any vaccine. This observation period allows healthcare staff to identify and treat anaphylaxis — the most serious immediate adverse reaction — which typically occurs within 15 minutes of injection. Syncope (fainting) is also more common in adolescents and young adults following vaccination; recipients are advised to sit or lie down during and after administration.

Managing Common Reactions at Home

• Injection site soreness: Apply a cool, damp cloth to the injection site. Avoid rubbing. Gentle movement of the arm can reduce stiffness.
• Fever: Age-appropriate antipyretics (paracetamol/acetaminophen or ibuprofen) can be used if fever causes distress. Note: routine prophylactic antipyretics are not recommended as they may reduce vaccine immunogenicity.
• Infant fussiness: Comfort feeding, holding, and skin-to-skin contact are effective non-pharmacological measures for vaccine-related infant distress.

When to Seek Medical Attention

Contact a healthcare provider promptly if the following occur within 48–72 hours of vaccination: high fever (>39.5°C / 103°F) that does not resolve with antipyretics; extensive redness or swelling extending beyond the joint proximate to the injection site; signs of anaphylaxis (difficulty breathing, throat tightening, hives, rapid heart rate, loss of consciousness); prolonged high-pitched crying in infants (>3 hours); or any other reactions causing significant concern.

Completing the Vaccination Schedule

Many vaccines require multiple doses spaced at specific intervals to achieve full protection. Adherence to the recommended schedule is important — doses given too early may not produce an adequate immune response in young infants, and excessive delays may leave individuals vulnerable during gaps in protection. Maintain a written or digital vaccination record and discuss any missed doses with your healthcare provider to arrange catch-up vaccination.

The cost of vaccination varies widely depending on geography, healthcare system, the specific vaccine, and whether it is covered under a national immunization program:

Publicly Funded Immunization

In countries with national health services or publicly funded immunization programs, vaccines on the national recommended schedule for children are typically provided at no cost to the patient at government health centres, community clinics, and designated primary care providers. In many countries, certain adult vaccines (annual influenza for high-risk groups, pneumococcal for elderly) are also publicly funded. GAVI (The Vaccine Alliance) subsidises essential childhood vaccines for 57 low- and middle-income countries, making immunization accessible regardless of national economic resources.

Private Sector and Out-of-Pocket Costs

When vaccines are obtained through private clinics, pharmacies, or travel health centres, patients typically pay out-of-pocket or claim through private health insurance. Representative cost ranges (USD) include:

• Routine childhood vaccines (single dose, private): USD 15–80 per injection depending on vaccine
• MMR (measles, mumps, rubella): USD 20–75 per dose
• Varicella: USD 30–90 per dose
• HPV (Gardasil 9): USD 150–300 per dose; 2–3 dose series total USD 300–900
• Annual influenza: USD 15–50
• Hepatitis A (2-dose series): USD 50–150 per dose
• Herpes zoster (Shingrix, 2-dose series): USD 150–220 per dose
• Travel vaccines (yellow fever, typhoid, Japanese encephalitis): USD 50–350 per dose

Insurance Coverage

In many countries, private health insurance plans cover vaccines on the national recommended schedule with no or minimal out-of-pocket cost. Coverage for travel vaccines varies by insurer. In the United States, the Affordable Care Act (ACA) requires most insurance plans to cover ACIP-recommended vaccines without cost-sharing. Individuals in the USA without insurance can access childhood vaccines through the Vaccines for Children (VFC) program at no cost.

While vaccination is the gold standard for preventing infectious diseases, there are specific clinical circumstances where alternative approaches are used, and it is important to understand their scope and limitations:

Passive Immunization (Immunoglobulins)

Pre-formed antibodies derived from human donors can be administered to provide immediate but temporary (typically 3–6 weeks) protection. This is used in post-exposure prophylaxis scenarios: rabies immunoglobulin (RIG) given with rabies PEP vaccine after an animal bite; hepatitis B immunoglobulin (HBIG) given to unvaccinated exposed individuals and to newborns of HBsAg-positive mothers; tetanus immunoglobulin (TIG) for wound management in unvaccinated individuals; and varicella-zoster immunoglobulin (VZIG) for high-risk susceptible contacts following exposure.

Antiviral and Antimicrobial Prophylaxis

For diseases without effective vaccines or in specific outbreak settings, chemoprophylaxis may be used: antiviral prophylaxis with oseltamivir (Tamiflu) during influenza outbreaks in high-risk residential settings such as nursing homes; malaria chemoprophylaxis (atovaquone-proguanil, doxycycline, chloroquine, or mefloquine) for travelers to endemic regions; and antibiotic prophylaxis following splenectomy to prevent overwhelming post-splenectomy infection by encapsulated organisms.

Natural Immunity

Immunity acquired through natural infection is not an acceptable alternative to vaccination. While natural infection generally induces durable immunity, acquiring immunity this way requires enduring the disease — with all its associated risks of complications, hospitalisation, disability, and death. For diseases such as measles, natural infection carries a 1 in 1,000 risk of encephalitis and approximately 1 in 500–1,000 risk of death in high-income settings, far exceeding any vaccine-associated risks. There are also no proven natural dietary, herbal, or homeopathic preparations that replicate the specific protective immunity conferred by vaccines.